Payment overview · 2025
General Payments
$658.72
28 reported records · 10 companies
Healthcare provider profile · identity verified
Rodolfo Guzman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · BRONX, NY · NPI 1205867835
Verified facts
What the public records show
CMS Open Payments records show Rodolfo Guzman, M.D. received $658.72 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 36.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro, Ozempic, Rybelsus, Synthroid, Veltassa.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Synthroid by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 294 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 574 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 296 claims for Rybelsus by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $241.96 | 36.7% | 10 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $123.00 | 18.7% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.52 | 15.3% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $46.98 | 7.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.84 | 6.3% | 2 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $30.00 | 4.5% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $23.03 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.95 | 2.9% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $17.66 | 2.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.78 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $658.72 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $221.37 | 9 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $123.00 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $100.52 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $46.98 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $41.84 | 2 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 294 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 261 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 296 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 226 | exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
172 | 42 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
226 | 68 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
294 | 77 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
574 | 126 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
198 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
261 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
296 | 67 |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
28 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1543 | 390 |
| Atorvastatin Calcium | Atorvastatin Calcium | 906 | 245 |
| Pioglitazone Hcl | Pioglitazone Hcl | 846 | 217 |
| Januvia | Sitagliptin Phosphate | 649 | 150 |
| Glipizide | Glipizide | 589 | 158 |
| Jardiance | Empagliflozin | 574 | 126 |
| Metformin Hcl | Metformin Hcl | 570 | 160 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 525 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 483 | 134 |
| Gabapentin | Gabapentin | 478 | 130 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 434 | 128 |
| Omeprazole | Omeprazole | 393 | 118 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 297 | 75 |
| Rybelsus | Semaglutide | 296 | 67 |
| Kerendia | Finerenone | 294 | 77 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 292 | 66 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 279 | 86 |
| Ozempic | Semaglutide | 261 | 41 |
| Farxiga | Dapagliflozin Propanediol | 257 | 59 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 246 | 73 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 226 | 58 |
| Synthroid | Levothyroxine Sodium | 226 | 68 |
| Alendronate Sodium | Alendronate Sodium | 211 | 60 |
| Ammonium Lactate | Ammonium Lactate | 203 | 45 |
| Trulicity | Dulaglutide | 198 | 34 |
| Tresiba Flextouch U-200 | Insulin Degludec | 185 | 41 |
| Ezetimibe | Ezetimibe | 180 | 46 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 173 | 46 |
| Linzess | Linaclotide | 172 | 42 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 169 | 43 |
| Vascepa | Icosapent Ethyl | 153 | 32 |
| Meloxicam | Meloxicam | 151 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 35 |
| Losartan Potassium | Losartan Potassium | 149 | 48 |
| Montelukast Sodium | Montelukast Sodium | 149 | 51 |
| Single Use Swab | Alcohol Antiseptic Pads | 148 | 48 |
| Simvastatin | Simvastatin | 146 | 44 |
| Lisinopril | Lisinopril | 143 | 42 |
| Novolog Flexpen | Insulin Aspart | 143 | 28 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 135 | 35 |
| Methimazole | Methimazole | 131 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 38 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 129 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 123 | 30 |
| Meclizine Hcl | Meclizine Hcl | 122 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 40 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 112 | 31 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 109 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 107 | 31 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 103 | 28 |
| Metformin Hcl Er | Metformin Hcl | 103 | 34 |
| Carvedilol | Carvedilol | 102 | 25 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 96 | 29 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 95 | 37 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 94 | 21 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 89 | 28 |
| Furosemide | Furosemide | 88 | 27 |
| Nifedipine Er | Nifedipine | 87 | 24 |
| Famotidine | Famotidine | 85 | 31 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 85 | 29 |
| Celecoxib | Celecoxib | 82 | 30 |
| Glimepiride | Glimepiride | 81 | 20 |
| Glipizide Er | Glipizide | 79 | 28 |
| Calcitriol | Calcitriol | 72 | 18 |
| Repaglinide | Repaglinide | 71 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 18 |
| Atenolol | Atenolol | 67 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 21 |
| Clonidine | Clonidine | 65 | 18 |
| Fenofibrate | Fenofibrate,micronized | 65 | 15 |
| Labetalol Hcl | Labetalol Hcl | 64 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 23 |
| Tradjenta | Linagliptin | 61 | 11 |
| Spironolactone | Spironolactone | 59 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 58 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 17 |
| Eliquis | Apixaban | 54 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 50 | 15 |
| Valsartan | Valsartan | 50 | 15 |
| Chlorthalidone | Chlorthalidone | 49 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 47 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 44 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 43 | 13 |
| Irbesartan | Irbesartan | 42 | 11 |
| Cilostazol | Cilostazol | 41 | 14 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 34 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 29 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 28 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 28 | 15 |
| Prednisone | Prednisone | 27 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 26 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Alogliptin-Pioglitazone | Alogliptin Benz/Pioglitazone | 25 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 25 | 13 |
| Finasteride | Finasteride | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 18 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Cabergoline | Cabergoline | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Alogliptin | Alogliptin Benzoate | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Veo Insulin Syringe | Syrge-Ndl,ins 0.3 Ml Half Mark | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $658.72 · 28 records | Novo Nordisk Inc | Dexcom G6 Transmitter, GLYCATE, Kerendia, MOUNJARO, Ozempic, RELTONE 200 MG, RELTONE 400 MG, REZDIFFRA, Rybelsus, SYNTHROID, TEPEZZA, UBRELVY, Veltassa, Yorvipath, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error